•   
  •   

UK News Valneva share rises 17%: Valneva Vakzine probably neutralizes omikron variant

18:40  20 january  2022
18:40  20 january  2022 Source:   finanzen.net

Biontech and Pfizer want to start testing for omikron vaccine before the end of January

 Biontech and Pfizer want to start testing for omikron vaccine before the end of January begin the vaccine manufacturer Pfizer and Biontech plan to test a vaccine adapted to the omikron variant before the end of January against the Corona virus to people. This explained by the scientific director of Pfizer to Business Insider. "We will test this from the end of January when we start clinical trials in which we compare the Omikron vaccine with the current vaccine," Mikael Dolfen said in a video interview on Monday.

The Corona vaccine of the French-Austrian biotech company Valneva, which is available from a possible approval, also acts against the Omikron variant of a study.

DANIEL ROLAND/AFP/Getty Images © Provided by finanzen.net Daniel Roland / AFP / Getty Images

The results of a first laboratory study showed that serum antibodies formed after three doses neutralizing the omikron variant, the Group announced on Wednesday evening.

All serum samples tested would show neutralizing antibodies against the original virus and the delta variant, while 87 percent also involved this against Omikron, the Group explained. "We are very satisfied with these results, which confirm the potential for a broad protection of our inactivated, adjuvant all-virus vaccine and its ability to currently circulating variants," said Valneva Chief Physician Juan Carlos Jaramillo. The new results would complement earlier findings of a Phase 3-Study, which showed that two doses show an improved immune response.

boss of the Corona crisis rod expects bottlenecks at tests

 boss of the Corona crisis rod expects bottlenecks at tests Munich. In the fight against the omikron wave, according to the head of the head of the Corona crisis rod of the Federal Government, the rapidly increasing infection numbers are expected to receive no longer sufficient test capacities for the entire population. © Martin Rugut Generalmajor Carsten Breuer (archive picture). "We will certainly have to bundle capacities as well as at all scarce resources where it is required," said Generalmaj Carsten Breuer of the "Süddeutsche Zeitung" (SZ).

The Group continues to expect an approval of its vaccine by the Health Authority EMA in the first quarter. First deliveries could then begin to start in April.

Valneva share shoots for vaccine neWS high

strong news from her Corona-david VLA2001 gave the papers of Valneva strong momentum on Thursday. After a loss of almost 20 percent at the Euronext at the middle of the week, they were temporarily shot up by up to 30 percent to almost 18 euros. Currently, the share certificates still note 17.74 percent stronger at 16.26 euros. Analyst Damien Choplain by Kepler Cheuvreux is quite sure that VLA2001 will find its place in the fight against Covid-19, and therefore sees a good gake. The data also underpinned the broad protecting spectrum of VLA2001 against mutations, so choplain. In the coming months, he expects some course drivers from admission to delivery agreements. Choplain's price target is 24 euros.

Fourth Corona vaccine: Who needs the booster after the booster?

 Fourth Corona vaccine: Who needs the booster after the booster? in Israel - pioneer at the Corona vaccinations - this fourth dose is already administered by Corona-endangered people . It causes a renewed increase in antibodies. Shortly after the fourth vaccination, it was again on the same level as shortly after the third, the Israeli data revealed.

At the end of November, Valneva papers had reached their previous high at almost 30 euros. The French are focused on investors because of their classic approach of VLA2001. They put on an inactive virus and are considered as an alternative for the vaccine keptother.

Last recently, vaccine values ​​such as Valneva, Biontech and Novavax had a serious stand. "The vaccine fair seems largely read," wrote the market observers of the Bernecken Stock Exchange Letters. From your point of view, it is therefore not worth it to jump to the Valneva train. According to a Börsian, however, this changed with the effectiveness shown against the omikron variant. The topic remains exciting.Ruters / Paris (DPA-AFX)

Corona: Politician criticize Bundestag Special Rule for Genese .
of the Genosis status is reduced from six to three months, but this does not apply to the Bundestag. Now criticism of the special rule - both of experts, as well as deputies itself. © Kay Nietfeld / DPA Since January 14, the Coronavirus has been subject to the Coronavirus infected in Germany only three instead of six months after the disease as recent . However, this does not apply to Members - a special rule continues to extend the genesen status for half a year.

usr: 0
This is interesting!